Interleukin-2 controlled release - Avadel Pharmaceuticals

Drug Profile

Interleukin-2 controlled release - Avadel Pharmaceuticals

Alternative Names: IL-2 XL

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Flamel Technologies
  • Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Renal cancer

Most Recent Events

  • 12 Dec 2007 IL-2 XL is available for licensing (
  • 10 Dec 2004 Phase-I/II clinical trials in Renal cancer in France (SC)
  • 02 Feb 2004 Preclinical trials in Cancer in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top